ANKE BIO(300009)2022-12-05 01:04Group 1: Company Performance - The company achieved stable growth in the first half of 2017, with a focus on its established business plan [2] - The biological products, particularly recombinant growth hormone, continued to grow rapidly due to high quality and effectiveness in treating children's growth issues [2] - Increased awareness and economic capability among residents contributed to the rising demand for growth hormone treatments [2] Group 2: Product Development and Marketing Strategies - The company is adapting its marketing strategies to promote interferon in various antiviral applications, leading to significant growth in external applications [3] - The revenue share from external interferon products has increased, contributing to a slight overall growth in interferon sales in the first half of the year [3] - The company is advancing the research and development of peptide formulations to enhance sales performance [3] Group 3: Research and Clinical Trials - The company is conducting clinical trials for monoclonal antibody drugs targeting Her-2 and PD-1, with promising prospects for broad anti-tumor efficacy [3] - The company is actively preparing for clinical submissions related to CAR-T technology, focusing on blood cancers and solid tumors [3]